Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
ConclusionsLenalidomide appears to be a promising therapeutic agent that offers the possibility of a novel combination of chemotherapy free regimen for patients with B-cell non-Hodgkin lymphoma.
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Hematology | Hormones | Lymphoma | Non-Hodgkin's Lymphoma | Revlimid | Rituxan | Science | Study